Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

Similar articles for PubMed (Select 11956426)


Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W.

J Urol. 2002 May;167(5):1995-2000.


Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.

Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ.

J Immunother. 2008 Jan;31(1):72-80.


B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.

Antonia SJ, Seigne JD.

World J Urol. 2000 Apr;18(2):157-63. Review.


Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192.


Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.

Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA.

J Immunother. 2002 Jul-Aug;25(4):359-72.


Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.


Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.

Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H.

J Transl Med. 2011 Oct 20;9:178. doi: 10.1186/1479-5876-9-178.


Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.

Hörig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL.

Cancer Immunol Immunother. 2000 Nov;49(9):504-14.


Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.


A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74.


Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent.

Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B.

Scand J Immunol. 1999 Sep;50(3):242-9.


Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.

Wang J, Nakamoto T, Kasaoka Y, Usui T, Hamada H.

Hiroshima J Med Sci. 2000 Mar;49(1):73-82.


Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.

Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Kopp J, Oberneder R, Blankenstein T, Schendel DJ.

Clin Cancer Res. 2005 Mar 1;11(5):1733-42.


A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer.

Veelken H, Mackensen A, Lahn M, Köhler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultze-Seemann W, Farthmann EH, Mertelsmann R, Lindemann A.

Int J Cancer. 1997 Jan 27;70(3):269-77.


Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.

Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK.

Cancer Biother Radiopharm. 2001 Feb;16(1):47-54.


Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S.

J Transl Med. 2009 Jan 7;7:2. doi: 10.1186/1479-5876-7-2.


Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.

Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER.

J Clin Oncol. 2004 Jul 15;22(14):2800-7.


Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.

Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG.

Hum Gene Ther. 2003 Mar 20;14(5):483-94.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk